Keymed Biosciences Future Growth
Future criteria checks 2/6
Keymed Biosciences is forecast to grow earnings and revenue by 16% and 49.7% per annum respectively. EPS is expected to grow by 17% per annum. Return on equity is forecast to be -44.7% in 3 years.
Key information
16.0%
Earnings growth rate
17.0%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 49.7% |
| Future return on equity | -44.7% |
| Analyst coverage | Good |
| Last updated | 19 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,256 | -444 | -685 | -418 | 9 |
| 12/31/2025 | 545 | -763 | -801 | -679 | 10 |
| 12/31/2024 | 141 | -756 | -954 | -614 | 10 |
| 6/30/2024 | 82 | -743 | -900 | -709 | N/A |
| 3/31/2024 | 218 | -551 | -767 | -506 | N/A |
| 12/31/2023 | 354 | -359 | -635 | -304 | N/A |
| 9/30/2023 | 341 | -313 | -587 | -250 | N/A |
| 6/30/2023 | 327 | -267 | -539 | -197 | N/A |
| 3/31/2023 | 214 | -287 | -610 | -299 | N/A |
| 12/31/2022 | 100 | -308 | -681 | -402 | N/A |
| 9/30/2022 | 155 | -281 | -661 | -349 | N/A |
| 6/30/2022 | 210 | -253 | -640 | -295 | N/A |
| 3/31/2022 | 160 | -2,070 | -514 | -255 | N/A |
| 12/31/2021 | 110 | -3,887 | -387 | -215 | N/A |
| 9/30/2021 | 55 | -4,149 | -269 | -169 | N/A |
| 6/30/2021 | N/A | -4,412 | -150 | -124 | N/A |
| 3/31/2021 | N/A | -2,615 | -145 | -122 | N/A |
| 12/31/2020 | N/A | -819 | -139 | -119 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 64Z is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 64Z is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 64Z is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 64Z's revenue (49.7% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: 64Z's revenue (49.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 64Z is forecast to be unprofitable in 3 years.